Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed
Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis
β Scribed by K.D Lindor; M.A Lacerda; R.A Jorgensen; C.K DeSotel; A.K Batta; G Salen; E.R Dickson; S.S Rossi; A.F Hofmann
- Book ID
- 118120870
- Publisher
- Nature Publishing Group
- Year
- 1998
- Tongue
- English
- Weight
- 262 KB
- Volume
- 93
- Category
- Article
- ISSN
- 0002-9270
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Statin therapy may target both hypercholesterolemia and cholestasis in primary biliary cirrhosis (PBC). However, little is known about the efficacy and safety of statins in PBC. The aim of this single-center study was therefore to prospectively examine the effects of atorvastatin on serum markers of
Ursodeoxycholic acid treatment of patients with primary biliary cirrhosis may lead to relief of pruritus and improvement of biochemical liver tests. The changes in serum and urinary bile acids induced by ursodeoxycholic acid treatment were studied. After 29 patients with primary biliary cirrhosis we